US Stock MarketDetailed Quotes

APLM Apollomics

Watchlist

0.205
-0.004-1.68%

Close Jul 22 16:00 ET

0.200
-0.005-2.49%

Post 19:59 ET

22.49MMarket Cap-106P/E (TTM)

Apollomics Stock Forum

Stock_Drift

Jul 17 20:07

7/18/24 🦍’s watchlist and HBD Sarah. 🎂
$Onconetix(ONCO.US)$ $SHINECO(SISI.US)$ $Apollomics(APLM.US)$ $Stardust Power(SDST.US)$ $Ampco-Pittsburgh(AP.US)$ $Psyence Biomedical(PBM.US)$ $NaaS Technology(NAAS.US)$
📊⚡️📊

Trwils1230

Jul 17 18:03

$Apollomics(APLM.US)$ got me an amc share. thx you

101569509

Jul 17 17:39

$Apollomics(APLM.US)$
going up

Trytosaveabit

Jul 17 16:15

$Apollomics(APLM.US)$ Im sure hoping some of my fantastic followers used that post yesterday to look for a spot to get in and got in? Ifn you did and you have the want to let me know? Could ya. That way i know to keep doing it? And most importantly i can congratulate you on a great trade!

Trytosaveabit

Jul 17 16:11

Just amazing what a 180 day extension can do!

$Apollomics(APLM.US)$ Hehehe

Mafiosa818

Jul 17 15:45

$Apollomics(APLM.US)$ 👀

Trwils1230

Jul 17 14:46

$Apollomics(APLM.US)$ these shorts are gunna get ripped lol

Trytosaveabit

Jul 16 15:52

Update

$Apollomics(APLM.US)$ Apollomics Granted 180-Day Extension to Regain Compliance With Nasdaq Minimum Bid Price Requirement

test dummy

Jun 17 10:58

$Apollomics(APLM.US)$ this rubbish delisted when?

Jaguar8

Jun 4 07:10

NEWS

$Apollomics(APLM.US)$
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall